Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Part of paid clinical trials in La Jolla, California.

Sponsor
Assuntina G. Sacco, MD
Study ID
NCT02769520
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression

Study Details

The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following locoregional disease recurrence.

Key Dates

Start date
Jul 6, 2016
Status verified
Jun 2025
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
27 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab
    Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression

Primary Outcome Measure

Disease-Free Survival [ Time Frame: 12 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
UCSD Moores Cancer CenterLa JollaCalifornia92093-
University of California San FranciscoSan FranciscoCalifornia94115-
University of California Los AngelesTorranceCalifornia90505-

Find similar trials in La Jolla, CA

By research site
UCSD Moores Cancer Center· La Jolla, CAUniversity of California San Francisco· San Francisco, CAUniversity of California Los Angeles· Torrance, CA

Related Studies